Market Signal Briefing

, /PRNewswire/ -- Southwest Airlines Co. (NYSE: LUV) welcomes Philippine Airlines (PAL) as the newest carrier partnering to connect transoceanic travelers with Southwest-operated flights. Dozens of new travel options across the Pacific are available now through Philippine Airlines and third-party travel booking sites.

Philippine Airlines serves airports across the Philippines, Asia, Australia, and the Middle East. In the United States, Philippine Airlines and Southwest® are working together to serve international travelers connecting through Los Angeles (LAX), Seattle/Tacoma (SEA), San Francisco (SFO), and Honolulu, Oahu (HNL), where Southwest operates nearly four dozen interisland arrivals and departures a day.

"Each airline partnership brings unique and incremental reach to places around the globe for both carriers and gives more consumers an opportunity to begin or end their journey with Southwest," said Andrew Watterson, Chief Operating Officer. "With nearly 90 flights a day in our schedule that touch the Hawaiian Islands and as California's largest air carrier1, Southwest is positioned like no other airline in serving Philippine Airlines' passengers arriving or departing the United States."

"Our interline partnership with Southwest Airlines enables seamless connections and single-ticket journeys across both of our networks," said Christoph Gaertner, Vice President of Revenue Management, Philippine Airlines. "As we continue to expand PAL's global reach, this collaboration provides more travel options and greater flexibility, giving our guests access to a wider range of destinations in the United States."

Southwest Airlines now partners with four overseas air carriers and is actively exploring additional transatlantic partnerships for later this year. Southwest is working to bring more choice and enhance the quality and quantity of travel experiences with Southwest, including a redesigned cabin experience and an ability to book assigned and extra legroom seating on flights operating from January 27, 2026.

ABOUT SOUTHWEST AIRLINES CO.

Southwest Airlines Co . operates one of the world's most admired and awarded airlines, offering its one-of-a-kind value and Hospitality at 117 airports across 11 countries. Southwest took flight in 1971 to democratize the sky through friendly, reliable, and low-cost air travel and now carries more air travelers flying nonstop within the United States than any other airline1. By empowering its more than 72,0002 People to deliver unparalleled Hospitality, the maverick airline cherishes a passionate loyalty among more than 140 million Customers carried in 2024. Southwest leverages a unique legacy and mission to serve communities around the world including harnessing the power of its People and Purpose to put communities at the Heart of its success. Learn more by visiting Southwest.com/citizenship.

Based on U.S. Dept. of Transportation quarterly Airline Origin & Destination Survey as of Q1 2025
Fulltime-equivalent active Employees as of September 30, 2025

ABOUT PHILIPPINE AIRLINES

Philippine Airlines (PAL) is the Philippines' flag carrier and only full-service network airline, as well as the first commercial airline in Asia. PAL's fleet of Boeing, Airbus, and De Havilland aircraft operate scheduled nonstop flights out of hubs in Manila, Cebu, Clark, and Davao to 31 destinations in the Philippines and 38 destinations in Asia, North America, Australia, and the Middle East. Known for its hallmark heartwarming and gracious Filipino service, PAL also supports the global economy through air cargo and charter services, while serving the travel needs of overseas Filipinos as well as businesspeople, tourists and families from all over the world.

SOURCE Southwest Airlines Co.

Pfizer Inc's (NYSE:PFE) lawsuit. Novo Nordisk A/S' (NYSE:NVO) counterbid. And in the middle of it all — a quiet $45 million position that might turn into Andreas Halvorsen's next masterstroke. After years of fighting from the sidelines of the Ozempic boom, Pfizer is finally throwing punches.

Pfizer is suing obesity-drug developer Metsera Inc (NASDAQ:MTSR) to block a takeover by Novo Nordisk. The war between the two pharma giants is driving MTSR stock higher, Wednesday.

Track MTSR stock here.
But while the pharma heavyweights slug it out, Viking Global, Halvorsen's $48 billion hedge fund, is quietly sitting on one of the most enviable seats in the house.

The $10 Billion PrizeNovo Nordisk just upped its bid for Metsera to $86.20 a share, valuing the biotech at roughly $10 billion, including a contingent value right of up to $24 in cash. Pfizer's offer, by comparison, tops out around $70 a share, and the company is fuming. CEO Albert Bourla didn't mince words on Tuesday's earnings call: "It is an illegal attempt by a foreign company to do an end run around antitrust laws, taking advantage of the government shutdown."

That meltdown underscores just how high the stakes have become in the race to dominate the next generation of weight-loss drugs — and how desperate Pfizer is to catch up to Novo's runaway success with Ozempic and Wegovy.

Read Also: Novo, Lilly, Pfizer: Who Wins If Trump Slashes Prices?

The Smart Money Got There FirstWhile Big Pharma battles in courtrooms and boardrooms, hedge fund titans are already counting their gains. Viking Global, which first disclosed its stake in Metsera at an average price of $27.22, is suddenly looking prescient.

Fellow billionaire Ken Griffin's Citadel also built a position earlier this year — small by Viking's standards, but now up more than 100%.

Metsera's proprietary nutrient-stimulated hormone analog peptides — a mouthful that might just redefine obesity treatment — have made it the biotech every pharma player suddenly wants to own.

The TakeawayPfizer's lawsuit may buy time, but it also signals fear. That is, fear of missing the next multibillion-dollar fat-loss franchise. Novo Nordisk wants to own it. Pfizer wants to stop it. But as the giants wrestle over who gets the future of weight-loss, Viking may already have it locked up.

Read Next:

HIMS CEO Says ‘A Little Bit of Craziness’ Is The Secret To Building A Global Health Platform
Photo: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Datadog Inc (NASDAQ:DDOG), a cloud-based monitoring and analytics platform for developers, will report its third quarter earnings on Thursday before US markets open, with Wedbush analysts expecting a robust performance driven by growing demand for observability and AI capabilities.

The analysts believe Wall Street’s consensus estimates, calling for revenue of $853.6 million and non-GAAP earnings per share of $0.45, “are relatively conservative.”

They pointed to the company’s growing AI initiatives and disciplined cost management. They also noted Datadog’s progress in expanding its customer base despite intensifying competition.

“Based on our recent checks, we believe that DDOG is coming away as a larger winner within the observability sector as the company improved its selling motion to win more deals across all market segments,” the analysts wrote.

They added that many competitors have experienced slower deal flow “largely in part to DDOG winning a larger number of deals,” which they wrote highlights the strength of Datadog’s software-as-a-service (SaaS) model.

AI continues to be a key driver for the company’s growth, Wedbush added. Datadog had about 4,500 customers using one or more AI-based products in the previous quarter, with spending among that group rising, Wedbush noted.

“The company is taking the AI Revolution head-on by integrating AI across its platform to enhance its customer offerings while investing strategically into new AI-driven products and features,” Wedbush wrote.

Wedbush has an ‘Outperform’ rating and $170 price target on Datadog, which traded hands at $157 on Tuesday afternoon.

The analysts see Datadog as “well-positioned to continue gaining share within the observability space” as enterprise usage of its AI and monitoring tools increases, calling Datadog “one of our favorite names to own as the AI Revolution takes hold.”

Q3: 2025-11-03 Earnings SummaryEPS of -$0.18 misses by $0.16

 |

Revenue of

$259.61M

(-14.72% Y/Y)

misses by $10.47M

Atlas Energy Solutions Inc. (AESI) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST

Company Participants

Kyle Turlington - Vice President of Investor Relations
John Turner - President, CEO & Director
Blake McCarthy - Chief Financial Officer
Ben Brigham - Founder & Executive Chairman
Tim Ondrak
Bud Brigham

Conference Call Participants

James Rollyson - Raymond James & Associates, Inc., Research Division
Derek Podhaizer - Piper Sandler & Co., Research Division
Stephen Gengaro - Stifel, Nicolaus & Company, Incorporated, Research Division
Doug Becker - Capital One Securities, Inc., Research Division
Keith MacKey - RBC Capital Markets, Research Division
Sean Mitchell - Daniel Energy Partners, LLC
Edward Kim - Barclays Bank PLC, Research Division
Lee Cooperman

Presentation

Operator

"

Kyle Turlington
Vice President of Investor Relations

"

John Turner
President, CEO & Director

"

Blake McCarthy
Chief Financial Officer

"

Ben Brigham
Founder & Executive Chairman

"

James Rollyson
Raymond James & Associates, Inc., Research Division

" Raymond James & Associates, Inc., Research Division

Derek Podhaizer
Piper Sandler & Co., Research Division

" Piper Sandler & Co., Research Division

Tim Ondrak

"

Stephen Gengaro
Stifel, Nicolaus & Company, Incorporated, Research Division

" Stifel, Nicolaus & Company, Incorporated, Research Division

Doug Becker
Capital One Securities, Inc., Research Division

" Capital One Securities, Inc., Research Division

Keith MacKey
RBC Capital Markets, Research Division

" RBC Capital Markets, Research Division

Sean Mitchell
Daniel Energy Partners, LLC

" Daniel Energy Partners, LLC

Edward Kim
Barclays Bank PLC, Research Division

" Barclays Bank PLC, Research Division

Bud Brigham

"

Lee Cooperman

" Omega Family Office

Operator

Greetings, and welcome to the Atlas Energy Solutions Third Quarter 2025 Financial and Operational Results Conference Call.

[Operator Instructions]

Please note, this conference is being recorded. I will now turn the conference over to your host, Kyle Turlington. Please go ahead.

Kyle Turlington
Vice President

Recommended For You

Q3: 2025-11-03 Earnings SummaryEPS of $0.03 beats by $0.06

 |

Revenue of

$101.10M

(8.83% Y/Y)

beats by $700.00K

Unitil Corporation (UTL) Q3 2025 Earnings Call November 4, 2025 2:00 PM EST

Company Participants

Christopher Goulding - Vice President of Finance and Regulatory
Tom Meissner - Chairman & CEO
Daniel Hurstak - Senior VP, CFO & Treasurer

Conference Call Participants

Matvey Tayts - Freedom Broker, Research Division

Presentation

Operator

Good day, and thank you for standing by. Welcome to the Third Quarter 2025 Unitil Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Chris Goulding, Vice President of Finance and Regulatory. Please go ahead.

Christopher Goulding
Vice President of Finance and Regulatory

Good afternoon, and thank you for joining us to discuss Unitil Corporation's Third Quarter 2025 financial results. Speaking on the call today will be Tom Meissner, Chairman and Chief Executive Officer; and Dan Hurstak, Senior Vice President, Chief Financial Officer and Treasurer. Also with us today are Bob Hevert, President and Chief Administrative Officer; and Todd Diggins, Chief Accounting Officer and Controller.

We will discuss financial and other information on this call. As we mentioned in the press release announcing today's call, we have posted information including a presentation to the Investors section of our website at unitil.com. We will refer to that information during this call.

The comments made today about future operating results or events are forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that can cause actual results to differ materially from those predicted.

Statements made on this call should be considered together with cautionary statements and other information contained in our most recent annual report on Form 10-K and other documents we have filed with or furnished to the Securities

Recommended For You

November 04, 2025 3:09 PM EST | Source: Hemostemix Inc.
Calgary, Alberta--(Newsfile Corp. - November 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from pain related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, is pleased to announce it has closed its first tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on October 8, 2025. The Company raised aggregate gross proceeds of $461,230 through the issuance of 4,193,000 units ("Units") at a price of $0.11 per Unit.

Each Unit consists of one common share in the capital of the Company (a "Common Share") and one common share purchase warrant (a "Warrant"). Each full Warrant entitles the holder to acquire one additional Common Share at a price of $0.15 per share for a period of two (2) years from the closing date of the Offering, subject to the accelerated expiry provision described below.

If, on any 10 consecutive trading days occurring after four months and one day has elapsed following the closing date, the closing sales price of the Common Shares (or the closing bid, if no sales were reported on a trading day) as quoted on the TSX Venture Exchange (the "Exchange") is greater than a weighted average price of $0.185 per Common Share, the Company may provide notice in writing to the holders of the Warrants by issuance of a press release that the expiry date of the Warrants will be accelerated to the date that is 30 days following such press release.

In connection with the Offering, the Company paid eligible finders aggregate cash finder's fees of approximately $23,698.40 and issued 215,440 finder's options (the "Finder's Options"). Each Finder's Option entitles the holder to purchase one Common Share at an exercise price of $0.15 per share for a period of 24 months from the closing date of the Offering.

The net proceeds of the Offering will be used for general working capital and to support ongoing operations, including the marketing and sales of VesCell™, the Company's proprietary stem cell therapy.

Certain directors of the Company, directly and indirectly, participated in the Offering, which constitutes a "related party transaction" within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101") and the policies of the Exchange. The Company is relying upon the exemptions from the formal valuation and minority shareholder approval requirements pursuant to sections 5.5(b) and 5.7(1)(a), respectively, of MI 61-101 on the basis that the Company is not listed on a specified stock exchange and, at the time the Offering was agreed to, neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the transaction insofar as it involves an interested party (within the meaning of MI 61-101) in the Offering, exceeds 25% of the Company's market capitalization calculated in accordance with MI 61-101.

The Offering is subject to all necessary regulatory approvals including acceptance from the Exchange. All securities issued in connection with the Offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.

Grand Rounds at the University of Florida - November 12, 2025

ABOUT HEMOSTEMIX

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in eleven peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 50% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit www.hemostemix.com.

For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: [email protected] / PH: 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the financing of the Company related to treatment of CLTI in Florida and the completion of the treatment of pain related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia with Angiogenic Cell Precursors (ACP-01) in furtherance of sales of VesCell™ (ACP-01), and the commercialization of ACP-01 via the sale of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273170

Key Takeaways Sterling's Q3 EPS rose to $3.48, topping estimates and up from $1.97 in the prior-year quarter.Revenues climbed 16% to $689M, driven by 58% growth in E-Infrastructure and 10% in Transportation.STRL raised 2025 EPS guidance to $10.35-$10.52 and EBITDA outlook to $486M-$491M.
Sterling Infrastructure, Inc. (STRL - Free Report) reported third-quarter 2025 results, wherein adjusted earnings and revenues surpassed the Zacks Consensus Estimate. Additionally, both metrics increased year over year.

The company’s third-quarter results were driven by robust performance across both segments, delivering strong revenue and EBITDA growth. This strong performance was mainly driven by a 58% increase in E-Infrastructure Solutions and a 10% increase in Transportation Solutions, which helped offset weaker performance in the Building Solutions segment.

Shares of Sterling risen 2.6% after trading hours yesterday, following the earnings release.

Inside Sterling’s Q3 HeadlinesSterling reported adjusted earnings of $3.48 per share, which topped the Zacks Consensus Estimate of $2.79 by 24.7%. In the year-ago quarter, the company reported adjusted earnings per share of $2.20.

Revenues of $689 billion also surpassed the consensus mark of $612 million by 12.5% and increased 16% from the year-ago figure of $594 million. Revenues increased 32% year over year, excluding RHB from the prior-year quarter.

Segmental Discussion of SterlingE-Infrastructure Solutions: Revenues (which consist of 60% of total revenues) from the segment were $417.1 million, up from the year-ago figure of $263.9 million. Adjusted operating income was $111.7 million, up 56.8% from $71.2 million in the year-ago quarter.

Transportation Solutions: For the reported quarter, the segment’s revenues amounted to $170.5 million, up 10% from $155.1 million in the year-ago period. Adjusted operating income was $26.7 million, indicating growth from the $19.1 million reported in the year-ago period.

Building Solutions: This segment’s revenues totaled $101.4 million, down 1.1% from $102.6 billion in the year-ago period. Adjusted operating income of $12.6 million was up 9.6% from $13.9 million in the year-ago period.

Sneak Peek at Sterling’s FinancialsAt the end of the third quarter, cash equivalents were $306.4 million, down from $664.2 million at the end of 2024. Long-term debt was $279.5 million at the third-quarter end against $289.9 million at the 2024-end.

In the third quarter of 2025, the company’s Adjusted EBITDA rose 47% year over year to $155.8 million, reflecting strong operational performance. Gross margin expanded 280 basis points to 24.7%.

As of the first nine months of 2025, net cash provided by operating activities was $253.9 million, down from $322.8 million in the prior-year period.

STRL’s Raised Outlook for 2025Adjusted earnings per share (EPS) are projected to be in the range of $10.35 to $10.52 (the prior expectation was $9.21 to $9.47). The company expects adjusted net income for the full-year 2025 to range between $321 million and $326 million (the prior expectation was $285 million to $294 million).

Sterling also anticipates adjusted EBITDA to be between $486 million and $491 million for the year (the prior expectation was $438 million to $453 million).

STRL’s Zacks Rank & Peer ReleasesSterling currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Masco Corporation (MAS - Free Report) posted lackluster third-quarter 2025 results, wherein the adjusted earnings and net sales missed the Zacks Consensus Estimate and tumbled year over year. The quarter’s performance was hurt due to the weak contributions from the Decorative Architectural Products segment, which outweighed the improved performance of the Plumbing Products segment.

The ongoing uncertainties in the global economy and tariff-related risks are restricting Masco’s near-term prospects. Masco expects net sales to be down in low single digits year over year, with an adjusted operating margin of approximately 16.5% (compared with 17.5% in 2024). Adjusted EPS is now expected to be between $3.90 and $3.95, compared with $3.90-$4.10 expected earlier. The revised range compares with the adjusted EPS of $4.10 reported in 2024.

 United Rentals, Inc.’s (URI - Free Report) third-quarter 2025 EPS missed the Zacks Consensus Estimate, while revenues beat the same. On a year-over-year basis, the top line increased, but the bottom line declined.

United Rentals reported record third-quarter revenues and adjusted EBITDA, driven by strong demand across construction and industrial end markets. Growth in both general rentals and specialty segments supported the results. Customer optimism, healthy backlogs and seasonal activity contributed to the overall strength. For 2025, United Rentals expects total revenues to be in the range of $16-$16.2 billion compared with $15.8-$16.1 billion expected earlier.

D.R. Horton, Inc. (DHI - Free Report) reported mixed fourth-quarter fiscal 2025 (ended Sept. 30, 2025) results, with earnings missing Zacks Consensus Estimate, while the total revenues beat the same. On a year-over-year basis, both metrics declined.

The continued housing market softness due to declining consumer confidence and affordability concerns marred D.R. Horton’s quarterly performance, resulting in lower home closings. Although the company is actively engaging in offering necessary sales incentives to drive traffic and incremental sales, it is adversely impacting the bottom line. Nonetheless, D.R. Horton’s strong liquidity, low leverage and national scale offer significant operational and financial flexibility.

Though TripAdvisor Inc (NASDAQ:TRIP) stock has pulled back from its Sept. 19, 52-week-high of $20.16, a short-term bounce could soon be on the way. The shares were last seen down 4.7% to trade at $14.68, a level that kept losses in check in October. Furthermore, the stock has come into contact with a historically bullish trendline.

Per Schaeffer's Senior Quantitative Analyst Rocky White, the equity is now within 0.75 of the 320-day moving average's 20-day average true range (ATR) after remaining above it 80% of the time during the last two weeks and 80% of the last 42 trading sessions. This signal has occurred two other times over the past 10 years, after which the stock was higher one month later 75% of the time with an average 15.9% gain. 

Short covering could give TRIP a lift as well. Short interest represents a whopping 21.9% of the stock's available float, and would take nearly 10 days to cover at its average pace of trading. 

SummaryBiotech stocks have rebounded after years of underperformance but remain well below their 2021 highs.Successful drug launches, strong trial results, and falling interest rates have boosted stock prices, while M&A activity pushes valuations higher.The biotech rally could be sustainable, analysts say, with biotech firms more disciplined and increasingly profitable, while startups avoid launching premature IPOs.SA Quant identified four Strong Buy biotech stocks with excellent momentum, outstanding collective investment fundamentals, and huge revenue and earnings growth potential.I am Steven Cress, Head of Quantitative Strategies at Seeking Alpha. I manage the quant ratings and factor grades on stocks and ETFs in Seeking Alpha Premium. I also lead Alpha Picks, which selects the two most attractive stocks to buy each month, and also determines when to sell them. Bill Oxford/E+ via Getty Images

Biotech stocks are showing signs of recovery after years of underperformance, supported by successful drug launches, faster FDA approvals, strong trial results, and falling interest rates. M&A activity has picked up and lifted biotech stocks in general as investors bet

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given that any particular security, portfolio, transaction or investment strategy is suitable for any specific person. The author is not advising you personally concerning the nature, potential, value or suitability of any particular security or other matter. You alone are solely responsible for determining whether any investment, security or strategy, or any product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. Steven Cress is the Head of Quantitative Strategy at Seeking Alpha. Any views or opinions expressed herein may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

Recommended For You

Hagerty, Inc. (HGTY) Q3 2025 Earnings Call November 4, 2025 10:00 AM EST

Company Participants

Jason Koval - Senior Vice President of Investor Relations & Communications
McKeel Hagerty - Chairman & CEO
Patrick McClymont - Chief Financial Officer

Conference Call Participants

Hristian Getsov
Charlie Lederer
Michael Phillips - Oppenheimer & Co. Inc., Research Division
Mitchell Rubin
Mark Hughes - Truist Securities, Inc., Research Division
Pablo Singzon - JPMorgan Chase & Co, Research Division
Thomas Mcjoynt-Griffith - Keefe, Bruyette, & Woods, Inc., Research Division

Presentation

Operator

Greetings, and welcome to the Hagerty Third Quarter 2025 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Jay Koval, Head of Investor Relations. You may begin.

Jason Koval
Senior Vice President of Investor Relations & Communications

Thank you, operator. Good morning, everyone, and thank you for joining us to discuss Hagerty's results for the third quarter of 2025. I'm joined this morning by McKeel Hagerty, Chief Executive Officer and Chairman; and Patrick McClymont, Chief Financial Officer.

During this morning's conference call, we will refer to an accompanying presentation that is available on Hagerty's Investor Relations section of the company's corporate website at investor.hagerty.com.

Our earnings release, slides and letter to stockholders covering this period are also posted on the IR website as well as our 8-K filing.

Today's discussion contains forward-looking statements and non-GAAP financial metrics as described further on Slide 2 of the earnings presentation. Forward-looking statements include statements about our expected future business and financial performance are not promises or guarantees of future performance.

They are subject to a variety of risks and uncertainties that could cause the actual results to differ materially from our expectations. For a discussion of material risks and important factors that could affect our actual results, please refer to those

Recommended For You

Silicon Laboratories Inc. (SLAB) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST

Company Participants

Giovanni Pacelli
Robert Johnson - CEO, President & Director
Dean Butler - CFO & Senior Vice President

Conference Call Participants

Tore Svanberg - Stifel, Nicolaus & Company, Incorporated, Research Division
Christopher Rolland - Susquehanna Financial Group, LLLP, Research Division
Cody Grant Acree - The Benchmark Company, LLC, Research Division
Kyle Bleustein - Barclays Bank PLC, Research Division
Quinn Bolton - Needham & Company, LLC, Research Division
Joseph Moore - Morgan Stanley, Research Division
Peter Peng - JPMorgan Chase & Co, Research Division

Presentation

Operator

Hello. My name is Didi, and I will be your conference operator today. Welcome to the Silicon Labs Third Quarter Fiscal 2025 Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I will now turn the call over to Giovanni Pacelli, Silicon Labs Senior Director of Finance. Giovanni, please go ahead.

Giovanni Pacelli

Thank you, Didi, and good morning, everyone. We are recording this meeting, and a replay will be available for 4 weeks on the Investor Relations section of our website at investor.silabs.com. Our earnings press release and the accompanying financial tables are also available on our website. Joining me today are Silicon Labs' President and Chief Executive Officer, Matt Johnson; and Chief Financial Officer, Dean Butler. They will discuss our third quarter financial performance and review recent business activities. We will take questions after our prepared comments, and our remarks today will include forward-looking statements that are subject to risks and uncertainties.

We base these forward-looking statements on information available to us as of the date of this conference call and assume no obligation to update these statements in the future. We encourage you to review our SEC filings, which identify important risk factors that could cause actual results to differ

Recommended For You

Harmony Biosciences Holdings, Inc. (HRMY) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST

Company Participants

Matthew Beck
Jeffrey Dayno - President, CEO & Director
Adam Zaeske - Executive VP & Chief Commercial Officer
Kumar Budur - Executive VP and Chief Medical & Scientific Officer
Sandip Kapadia - Executive VP, Chief Administrative Officer & CFO

Conference Call Participants

Ami Fadia - Needham & Company, LLC, Research Division
David Amsellem - Piper Sandler & Co., Research Division
Graig Suvannavejh - Mizuho Securities USA LLC, Research Division
Jay Olson - Oppenheimer & Co. Inc., Research Division
Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division
Danielle Brill Bongero - Truist Securities, Inc., Research Division
Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division
Ashwani Verma - UBS Investment Bank, Research Division
David Hoang - Deutsche Bank AG, Research Division

Presentation

Operator

Good morning. My name is Madison, and I will be your conference operator today. At this time, I would like to welcome everyone to Harmony Biosciences Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference may be recorded. [Operator Instructions]

I will now turn the call over to Matthew Beck. Please go ahead.

Matthew Beck

Thank you, operator. Good morning, everyone, and thank you for joining us today as we review Harmony Biosciences third quarter 2025 financial results and provide a business update.

Before we start, I encourage everyone to go to the Investors section of our website to find the materials that accompany our discussion today, including the reconciliation of our GAAP to non-GAAP financial measures. At this stage of our life cycle, we believe non-GAAP financial results better represent the underlying business performance.

Our speakers on today's call are Dr. Jeffrey Dayno, President and CEO; Adam Zaeske, Chief Commercial Officer; Dr. Kumar Budur, Chief Medical and Scientific Officer; and Sandip Kapadia, Chief Financial and Administrative Officer.

Recommended For You

November 04, 2025 14:08 ET

 | Source:

Almadex Minerals Ltd.

VANCOUVER, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Almadex Minerals Ltd. ("Almadex" or the "Company") (TSX-V: “DEX”) is pleased to provide a comprehensive overview of its diversified portfolio of royalties on precious and base metal projects throughout North America. Many of these royalties were generated through Almadex’s long-standing prospect generator model, providing shareholders with meaningful exposure to potential future discoveries and production while eliminating capital and operating risk.

Royalty Portfolio Overview
Almadex holds numerous net smelter return (NSR) royalties ranging from 0.5% to 2.0%, covering assets in Canada, the United States, and Mexico. This portfolio reflects over two decades of exploration success and partnership development by the Almadex team and its predecessor companies.

Key Royalty Interests

Canada

Dillard (British Columbia) – 2.0% NSR | Operator: Kodiak Copper Corp.
Covers the Dillard Zone, one of the mineralised zones forming part of the MPD initial resource estimate released by Kodiak Copper Corp. on August 12, 2025. Tim (Yukon) – 2.0% NSR | Operator: Silver North Resources Ltd. (Coeur Mining partner)
Almadex holds a 2% NSR royalty on the Tim Property, located 72 km west of Watson Lake, Yukon and 19 km northeast of Coeur Mining’s Silvertip Mine. The property is owned by Silver North Resources Ltd. (“Silver North”) and is currently being advanced under an option agreement by Coeur Mining, Inc. (“Coeur”), which can earn up to an 80% interest through staged exploration expenditures and a positive feasibility study. Ponderosa (British Columbia) – 2.0% NSR | Operator: AuGold Corp.
Gold-silver mineralization hosted within epithermal systems near Merritt, B.C., in the Spences Bridge Gold Belt. Prospect Valley (British Columbia) – 2.0% NSR | Operator: Westhaven Ventures Inc.
A gold-silver property within the Spences Bridge Gold Belt, proximal to Westhaven’s Shovelnose discovery. Skoonka Creek (British Columbia) – 2.0% NSR | Operator: Westhaven Ventures Inc.
Another asset in the Spences Bridge Gold Belt, offering exposure to a growing district of epithermal gold discoveries. Goz (Yukon) – 2.0% NSR | Operator: Silver North Resources Ltd.
Covers polymetallic (zinc-silver-copper-gold-lead) mineralization. Mor (Yukon) – 2.0% NSR | Operator: Silver North Resources Ltd.
Hosts stratabound base-metal mineralization and remains an attractive exploration target in Yukon’s Finlayson Lake district. Ram (Yukon) – 2.0% NSR | Operator: Long & Associates.
Early-stage gold-silver exploration in a geologically favourable setting, contributing additional upside to Almadex’s Yukon exposure. United States

Willow (Nevada) – 2.0% NSR | Operator: Abacus Mining & Exploration Corp.
A copper-gold porphyry target west of Nevada’s Yerington district, home to significant copper deposits. Drilling and geophysics have outlined strong porphyry indicators. Mexico

La Bufa (Chihuahua) – 2.0% NSR | Operator: Endeavour Silver Corp.
Covers gold-silver mineralization within one of Mexico’s prolific silver belts. Caballo Blanco (Veracruz) – 1.5% NSR | Operator: Candelaria Mining
A near-surface oxide gold-silver deposit originally discovered by Almadex’s technical team. The project remains one of eastern Mexico’s largest undeveloped precious-metal systems with district scale exploration potential. El Cobre (Veracruz) – 1.75% NSR | Operator: Azucar Minerals Ltd.
A large copper-gold porphyry alteration system with multiple mineralized centres along a four-to-five-kilometre trend. Cerro Colorado (Oaxaca) – 2.0% NSR | Operator: Gold Resource Corp.
Located near producing operations, this gold-silver project offers near-surface oxide potential with strong infrastructure and accessibility. El Encuentro (Sinaloa) – 2.0% NSR | Operator: McEwen Mining Inc.
Situated in a productive gold-silver belt, approximately 10km from McEwen’s El Gallo gold and silver mine. The project provides exposure to potential expansion of McEwen’s regional operations, and an annual advance royalty payment of $US33,332. El Fuego (Oaxaca) – 2.0% NSR | Operator: Gold Resource Corp.
Covers prospective ground within the same structural trend as producing gold-silver mines in Oaxaca, offering potential for future development. Los Venados (Sonora) – 2.0% NSR | Operator: Alamos Mining Corp.
Located in the Mulatos district, this property is prospective for epithermal and porphyry-style gold-silver mineralization adjacent to operating mines. Los Venados was purchased from Aloro Mining Corp through a mineral property purchase agreement dated May 7, 2025 (closure pending). Strategic Value and Outlook
Collectively, these royalties provide leverage to a wide range of projects at varying stages of exploration and development, operated by a diverse group of established and emerging companies. The portfolio offers exposure to gold, silver, copper, zinc, and lead, reflecting Almadex’s legacy, technical expertise and broad generative footprint.

“Our royalty portfolio captures two decades of exploration success and partnership creation,” stated Morgan Poliquin, Ph.D., P.Eng., President and CEO of Almadex Minerals. “From copper-gold porphyry systems like Kodiak’s Dillard Zone in British Columbia to silver-rich districts in Mexico and polymetallic projects in Yukon, Almadex is exposed to third-party success while preserving the financial strength to advance our own generative work.”

Technical and Third Party Information
Morgan J Poliquin, PhD, PEng, the President and CEO of Almadex and a Qualified Person as defined by National Instrument 43-101 ("NI 43-101"), has reviewed and approved the scientific and technical contents of this news release. The disclosure in this press release is based on information publicly disclosed by the owners or operators of these properties and information/data available in the public domain as at the date hereof and none of this information has been independently verified by Almadex. Although Almadex does not have any knowledge that such information may not be accurate, there can be no assurance that such third-party information is complete or accurate. Almadex’s royalty interests may cover less than 100% and sometimes only a portion of the publicly reported mineral reserves, mineral resources and production of a property.

About Almadex
Almadex Minerals Ltd. is a North American prospect generator and exploration company with a portfolio of projects, royalties, and in-house drilling capacity. Led by a team credited with multiple discoveries, Almadex applies a data-driven targeting model to explore for concealed porphyry copper-gold and epithermal gold-silver systems. The Company is well-financed, holds physical gold in treasury, and maintains exposure to numerous discovery opportunities through its exploration and royalty assets.

On behalf of the Board of Directors,

“Morgan J. Poliquin, Ph.D., P.Eng.”        

President and CEO
Almadex Minerals Ltd.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release includes forward-looking statements that are subject to risks and uncertainties. All statements within it, other than statements of historical fact, are to be considered forward looking. Forward-looking statements in this news release include, among other things, whether any of the royalties on precious and base metal projects throughout North America will materialize. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, permitting, continued availability of capital and financing, equipment availability and general economic, market or business conditions. The foregoing list of assumptions is not exhaustive. There can be no assurances that forward-looking statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. The Company does not assume any obligation to update any forward-looking statements, other than as required pursuant to applicable securities laws.

Contact Information:
Almadex Minerals Ltd.
Tel. 604.689.7644
Email: [email protected]
http://www.almadexminerals.com/

ScanSource, Inc. (SCSC - Free Report) is scheduled to report first-quarter fiscal 2026 results on Nov. 6, before market open.

The Zacks Consensus Estimate for the quarter’s revenues is pegged at $784.85 million, indicating growth of 1.2% from the prior-year quarter. The consensus mark for quarterly earnings currently stands at 91 cents per share, suggesting an improvement of 8% from the year-ago quarter. The estimates have remained unchanged over the past 60 days.

Image Source: Zacks Investment Research

SCSC’s Earnings Surprise HistoryScanSource’s earnings beat the Zacks Consensus Estimates in three of the trailing four quarters but missed in one. The company has a trailing four-quarter earnings surprise of 7.10%, on average. The trend is shown in the chart below.

Image Source: Zacks Investment Research

What the Zacks Model Unveils for SCSC StockOur proven model doesn’t conclusively predict an earnings beat for ScanSource this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here.

Earnings ESP: The Earnings ESP for ScanSource is 0.00%.

You can uncover the best stocks before they’re reported with our Earnings ESP Filter.

Zacks Rank: The company currently carries a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank stocks here.

Factors Likely to Have Shaped ScanSource’s Q1 PerformanceThe Specialty Technology Solutions segment serves channel sales partners in the United States, Canada and Brazil. The segment is seeing broad-based hardware growth in North America, led by double-digit growth in mobility and barcode, physical security, and managed connectivity. The segment also benefited from several large deals and the Advantix acquisition in the fourth quarter of fiscal 2025. We expect these factors to have continued in the first quarter of fiscal 2026 as well.

The Zacks Consensus Estimate for the Specialty Technology Solutions segment’s sales for the to-be-reported quarter is currently pegged at $752 million, suggesting in-line results with the year-ago quarter.

The Intelisys & Advisory segment provides sales and services to both channel sales partners (Intelisys) and end users (Advisory) in the United States. Net sales for the segment were up 1% in the last reported quarter, aided by the contribution from the Resourcive acquisition. We expect the acquisition to have likely contributed to the segment’s sales in the first quarter of fiscal 2026 as well.

The Zacks Consensus Estimate for the Intelisys & Advisory segment’s sales for the first quarter of fiscal 2026 stands at $24.4 million. It indicates a 5% improvement over the segment’s sales of $23.3 million in the year-ago quarter. ScanSource had guided low single digit growth in total revenues for the first half of fiscal 2026 citing the dynamic macro environment. Revenues are expected to pick up pace in the second half of fiscal 2026.

In September 2024, ScanSource had executed a cost reduction and restructuring program to align costs with demand, which is projected to result in approximately $10.5 million in annualized savings in selling, general and administrative expenses. In January 2025, it executed an additional cost reduction and restructuring plan, which will add to its savings in selling, general and administrative expenses.

Overall, modest revenue growth, combined with ongoing cost-saving measures, is expected to have driven improved earnings for the quarter.

ScanSource’s Price PerformanceSo far this year, shares of ScanSource have fallen 10.9% against the industry’s 0.2% growth.

Image Source: Zacks Investment Research

Stocks Poised to Beat Earnings EstimatesHere are some stocks, which according to our model, have the right combination of elements to post an earnings beat in their upcoming releases.

MasterCraft Boat Holdings (MCFT - Free Report) has an Earnings ESP of +4.08% and a Zacks Rank of 1 at present. MasterCraft Boat is scheduled to report its first-quarter fiscal 2026 results on Nov. 6.

The Zacks Consensus Estimate for MasterCraft Boat’s quarter’s earnings is 16 cents per share, suggesting year-over-year growth of 33.33%. MCFT has an average trailing four quarter earnings surprise of 397.22%.

Ralph Lauren (RL - Free Report) currently has an Earnings ESP of +0.67% and a Zacks Rank of 2. Ralph Lauren is slated to report its second-quarter fiscal 2026 results on Nov. 6.

The Zacks Consensus Estimate for Ralph Lauren’s to-be-reported quarter’s earnings is $3.45 per share, suggesting year-over-year growth of 35.8%. RL has an average trailing four-quarter earnings surprise of 8.49%.

Expedia Group (EXPE - Free Report) currently has an Earnings ESP of +8.44% and carries a Zacks Rank of 2. Expedia is set to report its third-quarter 2025 results on Nov. 6.

The Zacks Consensus Estimate for the quarter’s earnings is $7.21 per share, suggesting 17.6% growth. Expedia has an average trailing four-quarter earnings surprise of 3.40%.

NKE launches its 'Sport Offense' reorganization to boost innovation, streamline execution and reignite sustainable growth across its global portfolio.

Perplexity AI accused Amazon of "bullying" on Tuesday after it received a letter from the e-commerce giant demanding it prevent people from using its artificial intelligence browser Comet to make purchases on their behalf.

In a blog post, Perplexity said users can ask its Comet Assistant to find items and make purchases on Amazon, and that they "love this experience." But Perplexity said it received "an aggressive legal threat" from Amazon "demanding" that it put a stop to that practice.

Amazon has already taken steps in recent months to prevent external AI agents from crawling its website, including those developed by OpenAI, Google and Meta.

"Amazon should love this. Easier shopping means more transactions and happier customers. But Amazon doesn't care," Perplexity wrote. "They're more interested in serving you ads, sponsored results, and influencing your purchasing decisions with upsells and confusing offers." 

Amazon did not immediately respond to CNBC's request for comment.

Read more CNBC tech newsMicrosoft plans to hire more but with 'a lot more leverage' thanks to AI, CEO Satya Nadella saysWhile AI spending is top of mind, online ads are driving a lot of Big Tech's growthMicrosoft AI chief says only biological beings can be consciousMusk teases Tesla Roadster demo by year-end. He's been hyping a new one since 2017At the same time that Amazon is seeking to keep AI tools off its site, the company has launched its own offerings.

Last February, it rolled out a shopping chatbot called Rufus that can answer questions and suggest products. Amazon also began testing an agent in April called "Buy For Me" that lets shoppers purchase some products from other websites without leaving its app.

Perplexity is best known for its AI-powered search engine that gives users simple answers to questions and links out to the original source material on the web. The company initially launched Comet in July, and it rolled out for free worldwide in October.

Comet is supposed to serve as a personal assistant that can search the web, organize tabs, shop, draft emails and more, Perplexity said.

watch now

Norwegian Cruise Line posted higher quarterly sales and raised its full-year earnings outlook but said higher bookings from families were lowering its price mix. Shares fell.

MP's Q3 results are due Nov. 6, with revenues expected to fall 15.56% and earnings seen at a $0.14 loss per share.

Ball Corporation (BALL - Free Report) has reported third-quarter 2025 adjusted earnings per share (EPS) of $1.02, which came in line with the Zacks Consensus Estimate. The bottom line improved 12% year over year. The upside was driven by higher volumes across all segments.

On a reported basis, the company’s EPS from continuing operations was $1.18 compared with the prior-year quarter’s 63 cents.

Total sales were $3.38 billion in the reported quarter compared with $3.08 billion in the year-ago quarter. The top line beat the Zacks Consensus Estimate of $3.32 billion. Global aluminum packaging shipments were up 3.9% year over year.
 

Ball Corporation Price, Consensus and EPS Surprise

Ball Corporation price-consensus-eps-surprise-chart | Ball Corporation Quote

Ball Corp.’s Q3 Operational UpdateThe cost of sales was $2.7 billion, up 11.4% from the year-ago quarter. The gross profit totaled $678 million, up 3% from the year-ago quarter’s $657 million. The gross margin was 20.1%, a contraction from the prior-year quarter’s 21.3%.

Selling, general and administrative expenses decreased 8.5% year over year to $130 million. Comparable segment operating earnings were $437 million compared with the prior-year quarter’s $409 million.

BALL’s Q3 Segmental PerformancesThe Beverage Packaging North and Central America segment’s revenues increased 12.5% year over year to $1.64 billion in the third quarter on higher volume and price/mix. We predicted sales of $1.5 billion. Operating earnings amounted to $210 million, up 3% year over year. Our estimate for the segment's operating earnings was $179 million.

Sales in the Beverage Packaging EMEA segment were $1.06 billion, up 11% year over year. The reported figure beat our estimate of $991 million. The upside was driven by higher volume and favorable currency impact. Operating earnings were $147 million, marking 14.8% year-over-year growth. We projected operating earnings of $108 million.

The Beverage Packaging South America segment’s revenues rose 5% year over year to $508 million, driven by higher volumes. Our projection for the segment’s sales was $525 million. Operating earnings rose 2.6% to $80 million. The reported figure beat our estimate of $58.7 million.

Ball Corp.'s Cash Flow & Debt PositionThe company reported cash and cash equivalents of $0.57 billion at the end of third-quarter 2025, down from $1.44 billion at the end of the prior-year quarter. Cash generated from operating activities amounted to $51 million in the first nine-month period of 2025 against the cash outflow of around $385 million reported in the last year's comparable period.

The company’s long-term debt increased to $6.86 billion as of Sept. 30, 2025, from $5.35 billion as of Sept. 30, 2024.

The company so far in the year has returned $1.27 billion to shareholders through share repurchases and dividends. It remains on track to attain its target to return at least $1.5 billion to shareholders by the end of 2025. 

In August, Ball Corp. sold 41% of its 51% stake in Ball United Arab Can Manufacturing Company.

BALL’s Outlook For 2025The company expects growth in comparable earnings per share of 12-15% in 2025.

Ball Corp.’s Price Performance & Zacks RankBall Corp’s shares have lost 14.6% so far this year compared with the industry’s 6.4% decline.

Image Source: Zacks Investment Research

The company currently carries a Zacks Rank #4 (Sell). 

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Performances of BALL’s Peers in Q3Silgan Holdings Inc. (SLGN - Free Report) reported adjusted earnings of $1.22 per share in third-quarter 2025, beating the Zacks Consensus Estimate of $1.21. The bottom line increased 1% year over year and was within Silgan’s guidance of $1.18-$1.28.

Silgan’s total revenues increased year over year to $2.01 billion from the prior-year quarter’s $1.75 billion. The top line beat the Zacks Consensus Estimate of $1.93 billion.

Crown Holdings (CCK - Free Report) reported earnings of $2.24 per share, beating the Zacks Consensus Estimate of $1.98 per share. The bottom-line figure marked a 13% increase from $1.99 reported by Crown Holdings in the year-ago quarter. 

Crown Holdings posted revenues of $3.2 billion for the quarter, a 4% increase year over year.  It also beat the Zacks Consensus Estimate of $3.19 billion.

Sealed Air Corporation (SEE - Free Report) reported third-quarter 2025 adjusted earnings per share of 87 cents, which surpassed the Zacks Consensus Estimate of 68 cents. Sealed Air’s bottom line increased 10.1% year over year. 

Sealed Air’s total revenues were $1.35 billion, which beat the Zacks Consensus Estimate of $1.31 billion. The figure was up 0.5% year over year. 

Q3: 2025-11-03 Earnings SummaryEPS of $0.22 beats by $0.02

 |

Revenue of

$491.46M

(8.11% Y/Y)

misses by $15.93M

BB Seguridade Participações S.A. (OTCPK:BBSEY) Q3 2025 Earnings Call November 4, 2025 9:00 AM EST

Company Participants

Felipe Peres
Delano de Andrade - CEO, Member of the Executive Board & Director
Rafael Sperendio - CFO, Investor Relations Officer & Member of the Executive Board

Conference Call Participants

Tiago Binsfeld - Goldman Sachs Group, Inc., Research Division
Eduardo Nishio - Brasil Plural Corretora de Cambio, Titulose Valores Mobiliários S.A., Research Division
Gustavo Schroden - Citigroup Inc., Research Division
Marcelo Mizrahi - Banco Bradesco BBI S.A., Research Division
Maria Luisa Guede
Guilherme Grespan - JPMorgan Chase & Co, Research Division
Pedro Leduc - Itaú Corretora de Valores S.A., Research Division
Carlos Gomez-Lopez - HSBC Global Investment Research
Antonio Gregorin Ruette - BofA Securities, Research Division

Presentation

Felipe Peres

Good morning, welcome to our virtual meeting to present the results of the third quarter of 2025. This event is being recorded [Operator Instructions] This event will be divided in two parts. In the first part, our CEO, Delano Valentim and our CFO, Rafael Sperendio will present the main belief of the quarter. The presentation, either in Portuguese or in English can be downloaded from our Investor Relations website at the address www.bbseguridaderi.com.br.

In the second quarter of the event, there will be a Q&A session when analysts and investors will be allowed to ask questions. I will return after the presentation to give you instructions if you want to ask a question.

Now I would like to give the floor to Delano who is going to introduce himself as the new CEO of BB Seguridade and will share with you the main highlights of the quarter. Delano, floor is yours.

Delano de Andrade
CEO, Member of the Executive Board & Director

Thank you so much, Felipe. It's a great satisfaction to have you here for another BB Seguridade results presentation. where we will share

Recommended For You

Q3: 2025-11-04 Earnings SummaryEPS of -$0.09 misses by $0.25

Greenfire Resources Ltd. (GFR) Q3 2025 Earnings Call November 4, 2025 9:00 AM EST

Company Participants

Robert Loebach
Colin Germaniuk - President

Presentation

Operator

Good morning, ladies and gentlemen. Welcome to the Greenfire Resources Third Quarter 2025 Results Conference Call. [Operator Instructions] The conference is being recorded. [Operator Instructions].

I'll now turn the meeting over to Robert Loebach, Vice President, Commercial. Please go ahead, Robert.

Robert Loebach

Thank you, operator. Good morning, and welcome to Greenfire's conference call for our Q3 2025 results. Please note that today's call includes forward-looking statements and references non-GAAP and other financial measures. We encourage you to review the associated risks detailed in our latest MD&A. Unless specified otherwise, all monetary figures discussed today are in Canadian dollars. Capital expenditures and production figures presented today are based on our working interest net to Greenfire, unless noted otherwise.

Joining us on today's call are key members of the Greenfire team, including Adam Waterous, Executive Chairman; Colin Germaniuk, President; Jonathan Kanderka, Chief Operating Officer; Travis Belak, Vice President, Finance; and Riley Waterous, Principal at WEF and Observer on the Greenfire Board. Upon conclusion of our prepared remarks, we will open the floor to questions from research analysts.

I will now hand the call over to Colin.

Colin Germaniuk
President

Good morning, and thank you, everyone, for joining Greenfire's Q3 2025 Conference Call. On this morning's call, there are 3 topics I would like to discuss before opening up the call to questions from our analysts. First, I will provide an overview of Greenfire's recapitalization plan. Second, I will provide an update on Greenfire's current year operations. And third, I'll provide a progress update on our longer-term development plans.

As we have previously communicated with our stakeholders, it's no secret that we believe the business today has too

Recommended For You

Shares in Denny’s jumped 50% Tuesday after the 71-year-old diner chain — long known for its “Grand Slam” breakfasts and 24/7 service — agreed to go private in a $322 million deal.

The deal is being led by TriArtisan Capital Advisors, a New York-based private equity firm that also owns Chinese food chain PF Chang’s, the parent company of Hooters and burger place TGI Fridays.

Investment firm Treville Capital Group and Yadav Enterprises, one of Denny’s largest franchisees, are working with TriArtisan to buy out the restaurant chain.

Shares in Denny’s jumped 50% Tuesday after the diner chain agreed to go private in a $322 million deal. Getty Images
Stockholders will receive $6.25 a share in cash for each share – a 52% premium compared to its closing stock price on Monday.

Denny’s board of directors has unanimously approved the deal, which is expected to close in the first quarter of 2026.

The company conducted a review of strategic alternatives, reaching out to more than 40 potential buyers and receiving multiple offers, Denny’s Chief Executive Kelli Valade said.

For years, one of Denny’s biggest draws was its 24/7 service – including around-the-clock breakfast favorites.

But it paused those hours during the pandemic.

About a quarter of its 1,600 restaurants have not yet returned to those hours. Denny’s has eased up on the requirement, even though it was a fan-favorite among customers.

Over the past two years, Denny’s has shuttered 180 locations and launched a turnaround effort. scandamerican – stock.adobe.com
It’s also struggling to win over customers stunned by sticker shock, as more Americans choose to eat at home to save on cash.

Over the past two years, Denny’s has shuttered 180 locations and launched a turnaround effort including new menu items and restaurant remodels. 

Same-store sales slid 2.9% in the third quarter, the company said Monday.

Its revenue and earnings figures also missed Wall Street estimates.

Prior to Tuesday’s jump, the stock had fallen about 34% so far this year. It hit a 12-year low in February after a dismal decline in quarterly sales.

Key Takeaways ALL's Q3 EPS estimate of $8.20 is more double the prior-year quarter's reported figure.Growth in policies in force and investment income may drive revenue growth.Catastrophe losses and rising claims may pressure Allstate's underwriting margins.
The Allstate Corporation (ALL - Free Report) is scheduled to release third-quarter 2025 results on Nov. 5, after the closing bell. The Zacks Consensus Estimate for earnings is pegged at $8.20 per share, which has more than doubled from the prior-year quarter’s reported figure. 

The third-quarter earnings estimate has witnessed four upward revisions against no downward movement over the past 30 days. Meanwhile, the consensus mark for revenues is pegged at $17.4 billion, implying 5.9% growth from the year-ago quarter’s figure.

Image Source: Zacks Investment Research

ALL’s Earnings Surprise HistoryAllstate’s bottom line beat estimates in each of the trailing four quarters, the average surprise being 57.67%. This is depicted in the chart below:

What Our Quantitative Model Unveils for ALLOur proven model does not conclusively predict an earnings beat for Allstate this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, that’s not the case here, as you see below.

Earnings ESP: Allstate has an Earnings ESP of 0.00%. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.

Zacks Rank: ALL currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank stocks here.

Factors Likely to Shape Allstate’s Q3 ResultsAllstate’s revenues are expected to have gained on the back of improved net premiums earned as a result of higher policies in force. Policies in force are likely to have received an impetus from the acquisition of National General and improved direct sales. We estimate net earned premiums to grow 8.3% year over year to $15.5 billion in the third quarter. 

Net investment income is likely to have been driven by higher fixed income yields. The Zacks Consensus Estimate for net investment income is pegged at $832 million, which indicates a 6.3% improvement from the prior-year quarter’s reported figure. 

The Property-Liability segment is likely to have been aided by higher earned premiums, which, in turn, are expected to have stemmed from higher policies in force and new business growth. The consensus mark for the unit’s net premiums earned stands at $14.8 billion, suggesting 7.8% growth from the year-ago quarter’s reported number. 

However, continued incidence of catastrophe losses is expected to have hurt the overall underwriting results of Allstate in the third quarter. Management forecasts pre-tax catastrophe losses to be $558 million in the third quarter. 

The Protection Services segment is expected to have been aided by the strength in Allstate Protection Plans. The Zacks Consensus Estimate for the unit’s revenues is pegged at $899 million, which indicates an 8.1% improvement from the prior-year quarter’s reported figure. We expect the unit’s revenues to rise 7.6% year over year to $895.5 million. 

In the third quarter, underwriting results in the auto insurance and homeowners insurance businesses are expected to improve. 

Additionally, Allstate’s margins are likely to have suffered a blow due to elevated property and casualty insurance claims and claims expenses. We expect the abovementioned cost to increase 2.7% year over year to $10.7 billion.  

Stocks to ConsiderHere are some companies from the insurance space, which according to our model, have the right combination of elements to beat on earnings this time around:

HCI Group, Inc. (HCI - Free Report) has an Earnings ESP of +87.40% and a Zacks Rank of 2 at present. The Zacks Consensus Estimate for HCI’s third-quarter earnings is pegged at $2.35 per share, indicating a fivefold increase from the year-ago quarter’s figure.

HCI Group’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.70%.

Primerica, Inc. (PRI - Free Report) has an Earnings ESP of +2.27% and a Zacks Rank of 2 currently. The Zacks Consensus Estimate for PRI’s third-quarter earnings is pegged at $5.51 per share, indicating 3% decline from the year-ago quarter’s number.

Primerica’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.72%.

Essent Group Ltd. (ESNT - Free Report) has an Earnings ESP of +4.20% and a Zacks Rank of 3 currently. The Zacks Consensus Estimate for ESNT’s third-quarter earnings is pegged at $1.75 per share, indicating a 6.1% improvement from the year-ago quarter’s figure.

Essent Group’s earnings beat estimates in two of the trailing four quarters and missed the mark twice, the average surprise being 2.09%.

Information in Investor’s Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or performance. Authors/presenters may own the stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any specific investment strategies. Information is subject to change without notice. For information on use of our services, please see our Terms of Use.

*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet.

IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC.

©2025 Investor’s Business Daily, LLC. All Rights Reserved.

About Us

Who We Are
About Bernie Schaeffer
Our Newsroom
FAQ
Contact Us
Corrections
Ethics & Fact Checks Policy

Market News

Trade Alerts

Options 101

Deals

Deal of the Week
Broker Center
Free Trial

Log-In

Search

Macro tailwinds are blowing for the likes of Lockheed Martin, RTX, and others

Managing Editor

Nov 4, 2025
at 1:13 PM

Defense stocks came out of earnings season unscathed

Subscribers to Chart of the Week received this commentary on Sunday, November 2.

We’re more than halfway through earnings season, yet there’s only one sector out there that’s wrapped up its quarterly reports. Large cap defense contractors have stepped in and out of the earnings confessional, and the results – and long-term conclusions -- are worth unpacking.

Remember the two B’s when talking defense stocks: backlogs and budget. Backlogs signal future revenue potential and long-term stability. Think of it like knowing you have your best players locked up on long-term contracts, the excitement about the team increases, right? All of these companies reported backlogs at or near record-high levels.

Budgets matter and are as apolitical as they come. The total US national defense budget for fiscal year (FY) 2024 was $874 billion. The proposed budget for FY 2026 is over $1 trillion, with the Department of Defense requesting $1.01 trillion. There’s plenty of money to go around.

Unfortunately, it’s a good time to be a defense contractor. You’ve got the Russia-Ukraine conflict slogging on, a shaky ceasefire with Israel and Hamas, persistently icy tensions between China and Taiwan, and a Trump administration content with missile strikes on Venezuelan boats.

It’s no surprise that every name on this table below reported an earnings beat, and all of the War 4 RTX Corp (NYSE:RTX), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), General Dynamics Corp(NYSE:GD) hiked their full-year outlooks.

Blue chip LMT battling its year-to-date breakeven is interesting, especially as the rest of the sector soars. It’s also interesting that 14 of the 22 brokerages covering the stock maintain “hold” or worse ratings. With the U.S. Golden Dome project looming in 2026, will analysts suddenly change their tune?

Fellow Dow name RTX is consolidating below record highs, a move that’s resulted in new highs in the past.

GD, L3Harris Technologies Inc (NYSE:LHX), and Kratos Defense and Security Solutions Inc (NASDAQ:KTOS) are all on similar paths, with the latter two testing their respective bottom rails. NOC has fallen out of that same uptrend channel.

If you’re looking for exciting contrarian potential, keep moving. Ain’t nobody betting against these guys. Short squeeze potential is nonexistent with these established giants save for KTOS. Plus, there are no 14-Day relative strength indexes (RSI) in overbought or oversold territory.

With quarterly reports out of the way, post-earnings volatility crushes have options premium affordably priced, save for KTOS.

Huntington Ingalls Industries Inc (NYSE:HII) — the largest shipbuilder in the U.S. — gapped higher by nearly 7% on Thursday after a top-line beat and has that same price action as its larger peers. Yet eight of 11 analysts are on the sidelines with “hold” or “sell” ratings. Considering HII’s 12-month price target of $313.59 is a 1.4% discount to its current perch, overdue bull notes could keep the wind at the equity’s back.

Options traders are bearish on two names; GE, and NOC. Their respective 10-day put/call volume ratio of 1.05 and 1.07 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) rank in the 76th and 85th percentile of their annual ranges.

Honeywell’s spinoff of its specialty materials business occurred on Thursday, with the separation of its automation and aerospace arms on track for completion by the second half of 2026.

Factor in the encouraging backlogs across the board, and the U.S’ eagerness to spend on weapons, and there’s a lot to like about defense stocks going forward. But: if everyone is outperforming and has favorable technical setups, then who do you target?

It may feel like a cop out after this deep dive, but the iShares U.S. Aerospace & Defense ETF (ITA) and Global X Defense Tech ETF (SHLD) are up 70% and 82% year to date, respectively, and have exposure to all of the names outlined below.

Sometimes, when an entire sector looks great, and the differences between the players are semantics, you choose them all.

Pretty boring stuff, right? Buy and hold defense stocks through thick and thin? If you’re craving that sweet volatile price action, the outsized moves, let’s talk drones, or unmanned aerial vehicles (UAVs), or electric vertical take-off and landing aircraft (eVTOLs).

Drone demand is a multi-billion opportunity, valued at $15 billion in 2025 and projected to reach $29.8 billion by 2030.

For industry standard AeroVironment Inc (NASDAQ:AVAV) the shares are 10% off their Oct. 9 record high of $417.86, forming a flag pattern above their 30-day moving average. The drone maker won’t report earnings until Dec. 3, has 7% of its total available float sold short, and a buildup of options traders targeting puts.

Drones are the speculative side of defense stocks right now. Northrop and Kratos have invested considerable amounts of cheddar in their aeronautics systems, but if you want to take a big swing on some heavily-shorted names, specialists like AVAV, Joby Aviation (JOBY), Draganfly (DPRO), Red Cat Holdings (RCAT), Archer Aviation (ACHR), ZenaTech (ZENA), and EHang Holdings (EH) are all worth familiarizing with.

But that’s a deeper dive for another time.

Click Here to view the rest on Schaeffer’s Substack!

$40 = 4 Trades That Can Move the Needle

Start your trading week with a ready-to-execute trade hand selected by Schaeffer's very own Senior VP of Research Todd Salamone. 

Our Trade of the Week is backed by 30+ years of experience and will provide you the market insight, research, and trade management you need to act with confidence.

One month. 4 trades. Only $10 per trade!

👉 Click Here to Get Your First Trade Before Monday’s Opening Bell